Betaseron, Interferon Beta-1b News

Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,084,022 providing broad protection for stabilized formulations of alpha, beta, and gamma interferon suitable for non-invasive metered nasal spray delivery or traditional injection.

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial.

Nuron Biotech Exercises Option for a Licence to PolyTherics ' TheraPEGa Technology to Develop a Long-Acting Human Interferon beta-1b London, UK, 13 December 2011 - PolyTherics Limited , a provider of technology solutions to enable companies to develop better biopharmaceuticals, today announced that Nuron Biotech, Inc.

A Bayer Schering Pharma employee examines YAZ birth control pills in the company's factory in Berlin, Germany.

Objectives To investigate, during the 5-year period without treatment after termination of a 2-year clinical trial of interferon beta-1b for the treatment of primary progressive multiple sclerosis, differences in the evolution of clinical variables and magnetic resonance imaging results between trial arms and to investigate correlations between ... (more)